How PharmAla Biotech Holdings Inc. is positioning APA-01 around traumatic brain injury and neurorehabilitation
pharmadevicenews.comu/Firefly5647 — 11 hours ago
“When Resilient submits its updated data to the FDA, I hope the FDA prioritizes the review. It is the only program with completed Phase 3 trials for PTSD and is positioned to begin treating patients immediately following approval.”